VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$38.86
Market Cap
$4.51B
52W High
$42.79
52W Low
$27.16
ADV30
2,688,888
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
| Jun 2025 | 0 | — | -74,574,000 | -65,561,000 | 827,851,000 | 33,880,000 | 32,390,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-340,330,000
Investing CF
$332,332,000
Financing CF
$88,167,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,005,871,000
Inventory
—
Receivables
—
ST Investments
$484,848,000
EBIT TTM
$-501,998,000
Pretax Income TTM
$-472,335,000
Interest Exp TTM
—
Analysts
18
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | — | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | — | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | — | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | — | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | $4.49B | $26.22 | — |
| GIFLF | Grifols SA | $4.37B | $10.35 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.79B | $40.50 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.89B | $45.41 | — |
News headlines (Yahoo Finance, 1h cache)
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-07-10 21:45 · Yahoo
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data
2026-07-09 17:13 · Yahoo
3 High Growth GLP-1 Biotech Winners to Buy in July
2026-07-09 12:00 · Yahoo
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
2026-07-08 21:50 · Yahoo
Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run
2026-07-08 13:10 · Yahoo
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal
2026-07-08 09:12 · Yahoo
Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress
2026-07-08 07:13 · Yahoo
Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next
2026-07-08 06:12 · Yahoo
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
2026-07-08 05:11 · Yahoo
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
2026-07-07 20:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.